Thomas Cannell, Sesen Bio CEO
February 14, 2023 11:16 AM ESTUpdated 05:56 PM
Financing
Deals

Sesen Bio reach­es deal with in­vestor group, paving way for Caris­ma merg­er

Paul Schloesser

Associate Editor

With a new deal, Sesen Bio’s merg­er with CAR-M play­er Caris­ma Ther­a­peu­tics is fi­nal­ly get­ting the sig­nal to move for­ward.

The deal,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times